COVID-19 IgG Therapy

Kamada announced the availability of its plasma-derived Hyperimmune IgG Therapy for Coronavirus Disease (COVID-19), for compassionate use treatment in Israel. In addition, the company Intends to Initiate a Phase 1/2 Clinical Study in Hospitalized COVID-19 Patients in Israel and promote the path for FDA’s acceptance of a clinical development program.